Thyroid cancer (thyroid carcinoma) is a malignant growth of the thyroid gland. The vast majority of thyroid nodules is benign — thyroid cancer accounts for only a small proportion of all nodules.¹
The good news: the most common forms of thyroid cancer (papillary and follicular) have a very good prognosis. With early diagnosis and guideline-based treatment they are typically very curable.¹,²
Among the cancers with the best prognosis
Particularly papillary and follicular carcinomas are typically very curable with early diagnosis and guideline-based treatment.¹
2. Types
Thyroid carcinomas are classified by their tissue of origin and behaviour.¹
Differentiated carcinomas (common, good prognosis)
Papillary carcinoma
By far the most common form. Typically grows slowly. Preferentially metastasises to cervical lymph nodes. Prognosis typically very good.
Follicular carcinoma
Less common than papillary carcinoma. Can metastasise via the bloodstream to lung and bone. Prognosis typically good.
Oncocytic carcinoma (Hürthle cell)
Previously classified as a variant of follicular carcinoma; recognised as a separate entity since the WHO classification 2022.
Other forms
Medullary carcinoma (MTC)
Arises from the C-cells of the thyroid (calcitonin-producing cells). Can occur sporadically or hereditarily (MEN-2 syndrome). Calcitonin in blood is an important tumour marker.
Anaplastic carcinoma
Very rare but aggressive. Grows rapidly and typically responds poorly to conventional therapies. Prognosis unfavourable. New targeted therapies (BRAF/MEK inhibitors) can help in selected cases.
Poorly differentiated carcinoma (PDTC)
Sits in terms of aggressiveness between differentiated and anaplastic carcinoma.
3. Symptoms
Thyroid cancer typically causes no symptoms in early stages. It is most often detected incidentally during workup of thyroid nodules. Possible later signs:
Palpable or visible neck nodule
Rapid growth of a known nodule
Hoarseness — may indicate involvement of the recurrent laryngeal nerve
Difficulty swallowing or sense of pressure in the neck
Enlarged cervical lymph nodes
Back or bone pain — with distant metastases (rare at first diagnosis)
Warning signs requiring prompt assessment
A rapidly growing, hard neck nodule and/or new-onset unexplained hoarseness should be assessed promptly.
4. Risk factors
Radiation exposure: particularly neck irradiation in childhood (e.g. for other cancers) or radiation accidents. The most important known risk factor.
Family history: medullary carcinoma can occur hereditarily (MEN-2 syndrome, RET mutation). For differentiated carcinomas familial clustering is rarer but possible.
Pre-existing thyroid disease: goitre (enlarged thyroid) and nodule formation can slightly increase risk.
Sex and age: women are affected more often. Age at onset is typically between 30 and 60 years.
Iodine deficiency: can increase the risk of follicular carcinomas.
5. Diagnosis
Workup of suspicious thyroid nodules is the most common diagnostic pathway.¹
Ultrasound: assesses size, shape, echogenicity, margins and vascularity of the nodule. Standardised risk classification (e.g. EU-TIRADS, ACR-TIRADS) helps guide further management.
Fine-needle aspiration (FNA): sampling of cells from the nodule under ultrasound guidance. Cytological assessment (e.g. by Bethesda classification) determines further management.
Scintigraphy: shows whether a nodule is hormonally active (hot) or not (cold). Cold nodules carry a slightly elevated malignancy risk.
Calcitonin: measured in blood. Elevated levels can indicate medullary carcinoma. Some guidelines recommend this routinely in nodule workup.¹
Molecular diagnostics: genetic analysis of the aspirate (e.g. for BRAF, RAS mutations) can sharpen the diagnosis when cytology is indeterminate.
6. Treatment: surgery
Surgery is the primary treatment for thyroid cancer.¹
StandardSurgical procedures
Total thyroidectomy
Complete removal of the thyroid. Typically the standard procedure for differentiated thyroid cancer, particularly with tumours above a certain size or with risk factors.
Hemithyroidectomy
Removal of one thyroid lobe. May be sufficient for small, low-risk papillary carcinomas under certain conditions. Guidelines define when hemithyroidectomy is acceptable.¹
Lymph node dissection
Affected cervical lymph nodes are removed alongside. Central neck lymph node dissection is recommended in certain situations.
Possible complications — choose an experienced centre
Risks of thyroid surgery: recurrent laryngeal nerve injury (hoarseness) and hypoparathyroidism (parathyroid damage, low calcium). Risks depend strongly on surgeon experience — an experienced thyroid centre is recommended.
7. Treatment: radioiodine therapy
Radioiodine therapy (RAI) is used after surgery for differentiated thyroid carcinomas.¹
Principle
Radioactive iodine (I-131) is taken orally and concentrates selectively in residual thyroid tissue and iodine-avid metastases. The radiation destroys this tissue selectively.
Indication
Typically recommended for differentiated carcinomas after total thyroidectomy — to ablate residual thyroid tissue and destroy any remaining tumour cells. Indication depends on the risk profile (tumour size, lymph node involvement, distant metastases).
Not for everyone
For very small, low-risk papillary carcinomas, radioiodine therapy may be omitted under certain conditions.¹
Medullary and anaplastic carcinoma
These forms do not respond to radioiodine because they do not store iodine. Other treatment approaches are used instead (e.g. targeted therapies such as BRAF/MEK inhibitors for anaplastic carcinoma).
8. Follow-up and levothyroxine
Levothyroxine substitution
After total thyroidectomy lifelong substitution with levothyroxine is necessary. For differentiated carcinoma levothyroxine is typically dosed so that TSH is suppressed (TSH suppression) — because TSH can stimulate growth of any remaining tumour cells. The degree of suppression depends on risk profile.¹
Thyroglobulin (Tg)
The most important tumour marker for differentiated thyroid carcinomas in follow-up. Monitored regularly after total thyroidectomy and radioiodine therapy. A rise can indicate recurrence.
Ultrasound
Regular ultrasound of the neck (thyroid bed, cervical lymph nodes) is part of standard follow-up.
Follow-up intervals
Initially close follow-up (every three to six months), later at longer intervals with stable findings. Follow-up is lifelong.
Medication intake
Levothyroxine on an empty stomach in the morning, with a time gap from iron supplements, calcium and PPIs.
9. Prognosis
The prognosis of thyroid cancer depends strongly on the form.¹
Papillary carcinoma — very good prognosis; the vast majority of patients are cured
Follicular carcinoma — good prognosis; somewhat worse than papillary, but typically well treatable
Medullary carcinoma — prognosis depends on stage; with early diagnosis typically good
Anaplastic carcinoma — unfavourable prognosis; new targeted therapies can help in selected cases
Overall, thyroid cancer is among the cancers with the best prognosis. Many patients lead a normal life after successful treatment — with the qualification that levothyroxine must be taken for life and follow-up must be attended consistently.
How brite helps you with thyroid cancer
Levothyroxine on an empty stomach every morning, regular TSH and thyroglobulin checks, lifelong follow-up across endocrinology, nuclear medicine and oncology — life after thyroid cancer runs over decades. brite helps keep the overview.
Intake reminder — levothyroxine strictly on an empty stomach (at least thirty minutes before breakfast), calcium or iron with a time gap: brite reminds you on time. With TSH suppression, consistent daily intake is particularly important.
Drug interaction check — levothyroxine has many absorption interactions: iron, calcium, magnesium, PPIs (pantoprazole/omeprazole), soy products and some antacids reduce uptake. brite shows the critical combinations and the necessary time gaps.
Health journal — track TSH, thyroglobulin (the most important tumour marker), calcium and follow-up appointments over time. At the next endocrinology or nuclear medicine appointment, show the real picture — Tg stable or rising?
Digital medication plan — all medications clearly organised for endocrinology, nuclear medicine, oncology and GP. Particularly important before investigations with iodinated contrast media or before radioiodine therapy (low-iodine diet preparation).
The most common forms (papillary, follicular) are typically very curable with early diagnosis and guideline-based treatment. The prognosis is among the best of all cancers.¹
Not always. With small, low-risk papillary carcinomas, hemithyroidectomy (removal of one lobe) may be sufficient under certain conditions. With larger tumours or risk factors, total thyroidectomy is typically recommended.¹
After surgery, radioactive iodine (I-131) is taken; it concentrates in residual thyroid tissue and iodine-avid metastases and selectively destroys this tissue. Used for differentiated carcinomas. The treatment typically requires a short hospital stay.¹
Yes — after total thyroidectomy levothyroxine must be taken for life, since the body without a thyroid can no longer produce thyroid hormones. The dose is adjusted so that TSH is suppressed or kept in the normal range, depending on risk profile.
A protein produced only by thyroid tissue. After complete thyroid removal and radioiodine therapy, thyroglobulin should no longer be detectable in the blood. A rise during follow-up can indicate residual thyroid tissue or recurrence.¹
A rarer form of thyroid cancer arising from calcitonin-producing C-cells. Can occur sporadically or hereditarily (MEN-2 syndrome, RET mutation). Calcitonin in blood is the most important tumour marker. Does not respond to radioiodine.
Initially every three to six months (blood tests: TSH, thyroglobulin; neck ultrasound). With stable findings the intervals can be extended. Follow-up is lifelong — even after cure of thyroid cancer.
Recurrence is possible but relatively uncommon in differentiated carcinomas. Regular follow-up (thyroglobulin, ultrasound) serves to detect it early. Recurrences are typically well treatable.
Medical disclaimer: This article is for general information only and does not replace medical advice, diagnosis or treatment. Treatment of thyroid cancer should typically be carried out in a specialised centre. Levothyroxine after thyroid surgery must be taken for life and should not be self-adjusted or stopped without medical advice. Last updated: April 2026.
